{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:49:24Z","timestamp":1765381764023,"version":"build-2065373602"},"reference-count":48,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,4]],"date-time":"2012-01-04T00:00:00Z","timestamp":1325635200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:sec><jats:label\/><jats:p>Gender identity disorder (<jats:styled-content style=\"fixed-case\">GID<\/jats:styled-content>), or transsexualism, is an increasingly recognized medical condition with an expanding body of medical literature to support the use of established therapeutic guidelines. Transsexualism can be effectively managed through exogenous cross\u2010sex hormone administration used to induce development of desired sex characteristics, as well as use of other agents, such as aldosterone antagonists, aimed at decreasing physical characteristics of the undesired sex. Many complications can arise with the use of the available therapies, and these must be considered before determining the appropriate course of action. This review describes methods, including both pharmacotherapy and surgical interventions, for effective medical management of both male and female adults with <jats:styled-content style=\"fixed-case\">GID<\/jats:styled-content>. In addition, specific goals of therapy as well as safety aspects with long\u2010term use of pharmacotherapeutic agents are discussed. This review also discusses some special considerations for treating patients with significant, yet common, comorbid diseases such as human immunodeficiency virus infection, acquired immunodeficiency syndrome, and viral hepatitis, as these conditions may complicate the clinical course and preclude some patients from using certain therapies. Pharmacist involvement in the management of transsexualism can be extremely beneficial to patients and other health care providers. Pharmacists can help determine the appropriate therapy, optimize dosages, monitor for adverse effects, and educate patients on what to expect during their therapy. Pharmacists should become knowledgeable about guidelines and current literature on transsexualism, understand the monitoring parameters for safe and effective therapy, and establish themselves as partners in the collaborative management of this disorder.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.1006","type":"journal-article","created":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T03:30:42Z","timestamp":1346815842000},"page":"54-66","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Medical Management of Adult Transsexual Persons"],"prefix":"10.1002","volume":"32","author":[{"given":"Emily L.","family":"Knezevich","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice Creighton University School of Pharmacy and Health Professions"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura K.","family":"Viereck","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Creighton University School of Pharmacy and Health Professions"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andjela T.","family":"Drincic","sequence":"additional","affiliation":[{"name":"Division of Diabetes Endocrinology and Metabolism University of Nebraska College of Medicine Omaha Nebraska"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0345"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1008161"},{"key":"e_1_2_9_5_1","first-page":"1","article-title":"The Harry Benjamin International Gender Dysphoria Association's standards of care for gender identity disorders","volume":"5","author":"Meyer WJ","year":"2001","journal-title":"Int J Transgenderism"},{"volume-title":"The international statistical classification of diseases and health related problems","year":"1992","author":"World Health Organization","key":"e_1_2_9_6_1"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2004.02.006"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01821.x"},{"volume-title":"Endocrine therapy for transgender adults in British Columbia: suggested guidelines. Physical aspects of transgender endocrine therapy","year":"2006","author":"Dahl M","key":"e_1_2_9_9_1"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030520"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1809"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021967"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-865900"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000087751"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.8.6710"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215106001174"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.2601068.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2467"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018704630036"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2010.01.076"},{"key":"e_1_2_9_22_1","first-page":"353","article-title":"Estrogen\u2010induced severe acute pancreatitis in a male","volume":"5","author":"Perego E","year":"2004","journal-title":"J Pancreas"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01753.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03632.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2009.01.009"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0037-1614026","article-title":"Oral ethinyl estradiol, but not transdermal 17beta\u2010estradiol, increases plasma C\u2010reactive protein levels in man [letter]","volume":"84","author":"Giltay E","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14066-4"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018638715498"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yhbeh.2006.06.008"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-1038"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255074"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0289"},{"key":"e_1_2_9_33_1","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1001\/jama.1988.03720150054036","article-title":"Breast cancer in a male\u2010to\u2010female transsexual","volume":"259","author":"Pritchard TJ","year":"1988","journal-title":"JAMA"},{"key":"e_1_2_9_34_1","unstructured":"U.S. Food and Drug Administration.FDA drug safety communication: 5\u2010alpha reductase inhibitors (5\u2010ARIs) may increase the risk of a more serious form of prostate cancer. Available fromhttp:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm258529.htm. Accessed June 9 2011."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.09.001"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jomh.2008.05.001"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2847"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901366"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e328305081a"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0009922806296651"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jana.2010.02.004"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.2.4574"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-007-9299-3"},{"key":"e_1_2_9_44_1","unstructured":"Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents January 10 2011;1\u2013166. Available fromhttp:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. Accessed July 11 2011."},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328334444b"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000172271.78314.6d"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.3109\/13697130902952577"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800651212"},{"volume-title":"AndroGel (testosterone gel) product information","year":"2011","author":"Abbott Laboratories","key":"e_1_2_9_49_1"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2FPHAR.1006","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2FPHAR.1006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/PHAR.1006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:49:53Z","timestamp":1761058193000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/PHAR.1006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/PHAR.1006"],"URL":"https:\/\/doi.org\/10.1002\/phar.1006","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"2012-01-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}